C-CG0ZAspen Neuroscience
autologous iPSC, neuron replacement, advanced genomics
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-CG0Z
C-CG0ZC-CG0Zautologous iPSC, neuron replacement, advanced genomics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Aspen Neuroscience autologous iPSC, neuron replacement, advanced genomics
Aspen Neuroscience is a clinical-stage private biotechnology company developing iPSC-derived autologous neuron replacement therapies for Parkinson’s disease. Its lead product, ANPD001, is a personalized dopaminergic neuronal precursor cell therapy in a Phase 1/2a ASPIRO trial. The company uses patients’ own cells, machine learning, advanced genomics, and manufacturing automation to support scalable personalized cell therapy.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Aspen Neuroscience — Translational · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: phase 1. Band: translational. Modifiers: +5 depth (2 programs at…
Source: Deterministic